Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
P, EL, WB |
Positive control |
Breast |
Dilution |
2.5 µg/mL |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding an internal region of human PCNA protein |
PCNA (Proliferating Cell Nuclear Antigen)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
616-0350 |
-
|
Host |
Mouse |
Clone |
PC10 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2a kappa |
Localization |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
1 ml |
Concentrate |
CE/IVD |
MOB083 |
-
|
Host |
Mouse |
Clone |
PC10 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2a kappa |
Localization |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB083-01 |
-
|
Host |
Mouse |
Clone |
PC10 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG2a kappa |
Localization |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB083-05 |
-
|
Host |
Mouse |
Clone |
PC10 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG2a kappa |
Localization |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM014 |
-
|
Host |
Mouse |
Clone |
PC10 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG2a kappa |
Localization |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
25 ml |
Ready-to-use |
CE/IVD |
PDM014-25 |
-
|
Host |
Mouse |
Clone |
EH33 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
IgG2a+IgG1 kappa |
Immunogen |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Localization |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
1 ml |
Concentrate |
CE/IVD |
MOB573 |
-
|
Host |
Mouse |
Clone |
EH33 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
IgG2a+IgG1 kappa |
Immunogen |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Localization |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
0.1 ml |
Concentrate |
CE/IVD |
MOB573-01 |
-
|
Host |
Mouse |
Clone |
EH33 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
IgG2a+IgG1 kappa |
Immunogen |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Localization |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
0.5 ml |
Concentrate |
CE/IVD |
MOB573-05 |
-
|
Host |
Mouse |
Clone |
EH33 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
IgG2a+IgG1 kappa |
Immunogen |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Localization |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
6 ml |
Ready-to-use |
CE/IVD |
PDM573 |
-
|
Host |
Mouse |
Clone |
EH33 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
IgG2a+IgG1 kappa |
Immunogen |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Localization |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
25 ml |
Ready-to-use |
CE/IVD |
PDM573-25 |
-
|
Host |
Mouse |
Clone |
NAT105 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 kappa |
Localization |
Cytoplasmic |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3137AK |
-
|
Host |
Mouse |
Clone |
NAT105 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 kappa |
Localization |
Cytoplasmic |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
1 ml |
Concentrate |
CE/IVD |
ACI3137CK |
-
|
Host |
Rabbit |
Clone |
CAL20 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 |
Isotype |
Rabbit IgG1 |
Localization |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3224A |
-
|
Host |
Rabbit |
Clone |
CAL20 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 |
Isotype |
Rabbit IgG1 |
Localization |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3224B |
-
|
Host |
Mouse |
Clone |
NAT105 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG1 kappa |
Localization |
Cytoplasm |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
6 ml |
Ready-to-use |
CE/IVD |
API3137AA |
-
|
Host |
Rabbit |
Clone |
EP239 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Melanoma, colon cancer |
Dilution |
- |
Isotype |
IgG |
Localization |
Cytoplasm, cell membrane |
PD-1 (CD279)
|
Biocare Medical |
EP239 |
6 ml |
Ready-to-use |
CE/IVD |
API3162AA |
-
|
Host |
Rabbit |
Clone |
CAL20 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Rabbit IgG1 |
Localization |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
6 ml |
Ready-to-use |
CE/IVD |
API3224AA |
-
|
Host |
Mouse |
Clone |
ZM357 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Lymph Node |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /k |
Immunogen |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
Localization |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
1 ml |
Concentrate |
CE/IVD |
Z2424ML |
-
|
Host |
Mouse |
Clone |
ZM357 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Lymph Node |
Dilution |
- |
Isotype |
IgG1 /k |
Immunogen |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
Localization |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
7 ml |
Concentrate |
CE/IVD |
Z2424MP |
-
|
Host |
Mouse |
Clone |
ZM357 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Lymph Node |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /k |
Immunogen |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
Localization |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
0.5 ml |
Concentrate |
CE/IVD |
Z2424MS |
-
|
Host |
Mouse |
Clone |
ZM357 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Lymph Node |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /k |
Immunogen |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
Localization |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
0.1 ml |
Concentrate |
CE/IVD |
Z2424MT |
-
|
Host |
Rabbit |
Clone |
ZR3 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Placenta or lung adenocarcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
Localization |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
1.0 ml |
Concentrate |
CE/IVD |
Z2002RL |
-
|
Host |
Rabbit |
Clone |
ZR3 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Positive control |
Placenta or lung adenocarcinoma. |
Dilution |
- |
Isotype |
IgG |
Immunogen |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
Localization |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2002RP |
-
|
Host |
Rabbit |
Clone |
ZR3 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Placenta or lung adenocarcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
Localization |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2002RS |
-
|
Host |
Rabbit |
Clone |
ZR3 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Placenta or lung adenocarcinoma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
KLH-conjugated linear peptide corresponding tohuman PD-L1 |
Localization |
Cell membrane |
PD-L1
|
Zeta Corporation |
ZR3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2002RT |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
IHC(P), WB |
Pretreatment |
Citrate |
Positive control |
Heart |
Dilution |
2.5 µg/ml (~ 1:400) |
Isotype |
Rabbit IgG |
Immunogen |
A peptide corresponding to a 17 amino acid sequence from near the centre of Human CD274. |
PD-L1 (CD274)
|
Zytomed Systems GmbH |
polyclonal |
100 µg (100 µl) |
Purified |
RUO |
603-2389 |
-
|
Host |
Rabbit |
Clone |
CAL10 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung adenocarcinoma, tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 |
Localization |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3171A |
-
|
Host |
Rabbit |
Clone |
CAL10 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung adenocarcinoma, tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 |
Localization |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
1 ml |
Concentrate |
CE/IVD |
ACI3171C |
-
|
Host |
Rabbit |
Clone |
CAL10 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Lung adenocarcinoma, tonsil |
Dilution |
- |
Isotype |
IgG1 |
Localization |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
6 ml |
Ready-to-use |
CE/IVD |
API3171AA |
-
|
Host |
Rabbit |
Clone |
CAL10 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
CC1 |
Positive control |
Lung adenocarcinoma, tonsil |
Dilution |
- |
Isotype |
IgG1 |
Immunogen |
Peptide corresponding to the region within human PD-L1 |
Localization |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3171G |
-
|
Host |
Mouse |
Clone |
8003 (99/12) |
Format |
Purified |
Method |
EL |
Isotype |
Mouse IgG1 |
Immunogen |
Purified human Pepsinogen I |
Pepsinogen I
|
Zytomed Systems GmbH |
8003 (99/12) |
200 µg |
Purified |
RUO |
616-0101 |
-
|
Host |
Mouse |
Clone |
5B10 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Spleen |
Dilution |
1:10 - 1:20 |
Isotype |
Mouse IgG1 |
Immunogen |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
Localization |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
1 ml |
Concentrate |
CE/IVD |
MOB555 |
-
|
Host |
Mouse |
Clone |
5B10 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Spleen |
Dilution |
1:10 - 1:20 |
Isotype |
Mouse IgG1 |
Immunogen |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
Localization |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB555-01 |
-
|
Host |
Mouse |
Clone |
5B10 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Spleen |
Dilution |
1:10 - 1:20 |
Isotype |
Mouse IgG1 |
Immunogen |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
Localization |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB555-05 |
-
|
Host |
Mouse |
Clone |
5B10 |
Format |
ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Spleen |
Dilution |
--- |
Isotype |
Mouse IgG1 |
Immunogen |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
Localization |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
6 ml |
ready-to-use |
CE/IVD |
PDM555 |
-
|
Host |
Monospecific Mouse |
Clone |
ZM159 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Spleen. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG /κ |
Immunogen |
Recombinant human Perforin protein fragment (around aa 413-552) |
Localization |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
1 ml |
Concentrate |
CE/IVD |
Z2472ML |
-
|
Host |
Monospecific Mouse |
Clone |
ZM159 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Spleen. |
Dilution |
- |
Isotype |
IgG /κ |
Immunogen |
Recombinant human Perforin protein fragment (around aa 413-552) |
Localization |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
7 ml |
Ready-to-use |
CE/IVD |
Z2472MP |
-
|
Host |
Monospecific Mouse |
Clone |
ZM159 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Spleen. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG /κ |
Immunogen |
Recombinant human Perforin protein fragment (around aa 413-552) |
Localization |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
0.5 ml |
Concentrate |
CE/IVD |
Z2472MS |
-
|
Host |
Monospecific Mouse |
Clone |
ZM159 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Spleen. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG /κ |
Immunogen |
Recombinant human Perforin protein fragment (around aa 413-552) |
Localization |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
0.1 ml |
Concentrate |
CE/IVD |
Z2472MT |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Melanoma |
Dilution |
1:100 - 1:200 |
Isotype |
not determined |
Localization |
Nucleus |
Phospho-Histone H3 (pHH3)
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
CP404A |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Melanoma |
Dilution |
1:100 - 1:200 |
Isotype |
not determined |
Localization |
Nucleus |
Phospho-Histone H3 (pHH3)
|
Biocare Medical |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
CP404C |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Melanoma |
Dilution |
- |
Isotype |
not determined |
Localization |
Nucleus |
Phospho-Histone H3 (pHH3)
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PP404AA |
-
|
Host |
Rabbit |
Clone |
BC37 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil, melanoma |
Dilution |
1:100 - 1:200 |
Isotype |
Rabbit IgG |
Localization |
Nucleus (mitotic figure) |
Phospho-Histone H3 (pHH3) (RM)
|
Biocare Medical |
BC37 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3130A |
-
|
Host |
Rabbit |
Clone |
BC37 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil, melanoma |
Dilution |
1:100 - 1:200 |
Isotype |
Rabbit IgG |
Localization |
Nucleus (mitotic figure) |
Phospho-Histone H3 (pHH3) (RM)
|
Biocare Medical |
BC37 |
1 ml |
Concentrate |
CE/IVD |
ACI3130C |
-
|
Host |
Rabbit |
Clone |
BC37 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil, melanoma |
Dilution |
- |
Isotype |
Rabbit IgG |
Localization |
Nucleus (mitotic figure) |
Phospho-Histone H3 (pHH3) (RM)
|
Biocare Medical |
BC37 |
6 ml |
Ready-to-use |
CE/IVD |
API3130AA |
-
|
Host |
Rabbit |
Clone |
ZR292 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Neuroblastoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment of human PHOX2B protein |
Localization |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
1 ml |
Concentrate |
CE/IVD |
Z2730RL |
-
|
Host |
Rabbit |
Clone |
ZR292 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Neuroblastoma |
Dilution |
- |
Isotype |
IgG |
Immunogen |
Recombinant fragment of human PHOX2B protein |
Localization |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
7 ml |
Concentrate |
CE/IVD |
Z2730RP |
-
|
Host |
Rabbit |
Clone |
ZR292 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Neuroblastoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment of human PHOX2B protein |
Localization |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
0.5 ml |
Concentrate |
CE/IVD |
Z2730RS |
-
|
Host |
Rabbit |
Clone |
ZR292 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Neuroblastoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment of human PHOX2B protein |
Localization |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
0.1 ml |
Concentrate |
CE/IVD |
Z2730RT |
-
|